Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Course Is Clearer Following Bush Victory

This article was originally published in The Pink Sheet Daily

Executive Summary

President Bush's victory in the Nov. 2 election means that the Centers for Medicare & Medicaid Services will have a chance to create a stand-alone drug insurance program under Medicare

You may also be interested in...



CMS Claims Too Much Authority Over Medicare Rx Prices – PhRMA

The Centers for Medicare & Medicaid Services incorrectly interprets the Medicare Modernization Act to allow "justification of aggregate price levels for groups of drugs," PhRMA asserts in comments on CMS' proposed Part D regs.

Medco Will Work With CMS On Medicare Rules: Backpedaling From "Fallback"?

Medco has been asked by CMS to offer constructive ideas to help make private drug insurance work, and company says it intends to do that in commenting on Part D regulations. However, CEO suggests Medco remains most interested in working under Medicare Advantage and through "fallback" plan.

Kerry Medicare Rx "Overhaul" May Include PBMs To Negotiate On Behalf Of HHS

Democratic presidential candidate wants to find a way to use federal government's bulk purchasing leverage through private contractors to conduct genuine "negotiations" for drugs – not set prices, staffer says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel